Metanalysis (60 RCTs; 20,418 SpA & PsA pts Rx 17 b/tsDMARDs) shows increased NonSerious infections (RR 1.15), @higher doses, longer Rx; mainly URI & ENT infxn, Signif for axSpA (RR 1.32), not PsA(RR 1.05). SIE were NOT increased https://t.co/Ab9Q9NRFu3 https://t.co/Gzoe3sRaXp

Swedish registry shows #PsA mortality risk ~11% (HR 1.11) higher than general pop., driven by comorbidity, esp in women (HR: 1.23) w/ longer Dz duration (HR: 1.18). Causes of death lead by CV Dz and malignancy. https://t.co/M6muM2UIkN https://t.co/az3kig9pBu

Here’s what will change my practice in Rheumatoid Arthritis https://t.co/7L1QFSVzpe https://t.co/hmR3VOyKls

Race to the top: how high will treatment response rates in RA reach? We have become used to the 60/40/20% rule for the outcome of ACR 20/50/70 for biologics and targeted synthetic DMARDs. https://t.co/VJplM5GC31 https://t.co/gNsN3wX5tA

2023 EULAR #PMR referral recommendations: 1 Suspected/Dx pts: consider Rheum eval 2 Do full Hx+PE+Labs before referral 3 Refer Severe Sx PMR to rapid access 4 Defer steroids til rapid Rheum eval 5 Rheum Dx PMR w? +steroid response can be Rx by PCP https://t.co/42bL8BL3QJ https://t.co/ffpKoKXZJM

Withdraw DMARDS after remission? Considering withdrawing DMARDs after remission is on our minds. When patients inquire about tapering or stopping DMARDs while doing well, we often lack a clear-cut answer. https://t.co/mQKhwv9wCt https://t.co/Q57t63vNKe

Calcineurin Inhibitors in Lupus Nephritis Dr. Kathryn Dao discusses abstract 1509 with Dr. Gabriel Figueroa-Parra at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/4CjJ8Ri3ym https://t.co/KUONVdMfBB

How do we Diversify Clinical Trials? Dr. Rachel Tate talks with Dr. Irene Blanco at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/fZ7kKfdRwP https://t.co/Non3X7zOxA

Is MTX Safe in the Elderly? Dr.Cush reviews this past week's news from RheumNow. Good news is that nearly 99% of adult rheumatology positions matched! But 45% of pediatric fellowship programs and 39% of pediatric rheum slots were unfilled. https://t.co/un9CbyYooL https://t.co/ilABvgr7bH

Pneumocystis Jiroveci Pneumonia (PJP) Risk https://t.co/6kP3IjmHi1 https://t.co/ERwIeTKBYp

resolved HBV (HBsAg-, HBcAb+, HBsAb+) are at low risk of reactivation (~2%) w/ TNFi or biologics. But in a high risk endemic region (ie, Korea) this risk is higher. Study of 416 such pts HBV reactivation rate 3.5% @5 yrs, 6.1% @10 yrs & 24.2% @17 yrs https://t.co/oQ5e6O9wds https://t.co/50vBtapJVN

Risk of Hepatitis B reactivation is assessed by serology - Resolved HBV (low risk reactiv): HBsAg-neg, HBcAb–pos & Pos HBsAb - If HBcAb(+), HBsAb negativity incr risk; - HBsAg(-), HBcAb(+), HBsAb(-) negative= resolved infx, occult infx, chronic hepatitis https://t.co/91ZwqWkdvo https://t.co/c23nN8ER1Y